Scientists Identify Hundreds of Mutation Patterns Offering New Insights into Cancer Development and Targeted Therapy Opportunities

Scientists Identify Hundreds of Mutation Patterns Offering New Insights into Cancer Development and Targeted Therapy Opportunities

(IN BRIEF) Researchers from The Institute of Cancer Research and The University of Manchester have created the most comprehensive map of cancer-related genetic mutations to date, analysing data from nearly 11,000 patients in the 100,000 Genomes Project. The study identified 134 mutational signatures, including 26 newly discovered ones, and catalogued around 370 million mutations across multiple cancer types. The findings reveal that more patients may benefit from targeted therapies due to previously under-recognised DNA repair deficiencies. Additionally, the research provides new evidence linking gut bacteria to rising rates of early-onset bowel cancer. Overall, the study advances understanding of cancer development and supports the future of more precise, personalised treatment approaches.

(PRESS RELEASE) LONDON, 30-Mar-2026 — /EuropaWire/ — A major international research effort led by The Institute of Cancer Research London and The University of Manchester has produced the most detailed map to date of the genetic mutations that drive cancer. The findings, published in Nature Genetics, provide new insights that could expand access to precision treatments and help explain the increasing incidence of bowel cancer among younger individuals.

The study analysed whole-genome sequencing data from nearly 11,000 cancer patients within Genomics England’s 100,000 Genomes Project, one of the largest initiatives of its kind. Researchers examined hundreds of millions of mutations across 16 different cancer types, identifying 134 distinct mutational “signatures” — unique patterns of DNA damage that reveal how cancers develop. Of these, 26 signatures had not previously been identified.

In total, the research team catalogued approximately 370 million mutations across the human genome, offering an unprecedented view of the genetic alterations that accumulate as tumours evolve over time.

One of the most important findings relates to homologous recombination deficiency (HRD), a weakness in the DNA repair process that can make tumours more responsive to specific treatments such as PARP inhibitors and platinum-based chemotherapy. The study found HRD in 16% of breast cancers and 14% of ovarian cancers, suggesting that significantly more patients could benefit from targeted therapies than previously estimated based solely on BRCA1 and BRCA2 mutation testing.

The research also provides new evidence supporting a potential link between gut bacteria and the rise of early-onset bowel cancer. A mutational signature associated with toxins produced by certain bacterial strains was found more frequently in younger patients, unlike many other signatures that accumulate with age. This finding points to the possible role of microbial factors in driving cancer development in younger populations, although further research is needed to fully understand the mechanisms involved.

Richard Houlston, Head of Cancer Genomics at The Institute of Cancer Research, highlighted the significance of the findings, noting that analysing the complete genetic history of tumours provides valuable insights that can inform patient care. He emphasized that understanding the patterns behind mutations, rather than focusing solely on individual genetic changes, will be key to advancing cancer treatment.

David Wedge, Professor of Cancer Genomics and Data Science at The University of Manchester, added that different causes of DNA damage leave distinct signatures in the genome. By studying entire genomes rather than isolated mutations, researchers can better predict which therapies are most likely to be effective for individual patients.

The study received support from the NIHR Manchester Biomedical Research Centre and represents a significant step forward in understanding cancer biology, with implications for improving diagnosis, treatment, and prevention strategies.

Media Contact:

Tel: 0203 437 3502
email: mediaoffice@icr.ac.uk

SOURCE: The Institute of Cancer Research